Brian Park, PharmD

Drug Information Specialist https://www.pulmonologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

News

Homeopathic Med Used for Snoring Recalled Due to Microbial Contamination

Brian Park, PharmD

June 13, 2022

SnoreStop NasoSpray is a nasal spray used to temporarily help stop or reduce symptoms of nonapneic snoring.

Asthma

Albuterol/Budesonide Fixed-Dose Combo Rescue Inhaler to Get FDA Review

Brian Park, PharmD

June 8, 2022

The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma.

General Medicine

Abatacept, Infliximab Improved Survival in Adults Hospitalized With COVID-19

Brian Park, PharmD

June 6, 2022

The ACTIV-1 Immune Modulators trial was led by the NIH and enrolled 1971 hospitalized adults with moderate to severe COVID-19.

Influenza

FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV

Brian Park, PharmD

May 20, 2022

The test is the first non-prescription multi-analyte COVID-19 test that allows individuals to test nasal swab samples self-collected at home.

Lung Cancer

Trastuzumab Deruxtecan Gets Priority Review for Previously Treated HER2-Mutant Metastatic NSCLC

Brian Park, PharmD

May 4, 2022

The FDA has granted Priority Review to fam-trastuzumab deruxtecan-nxki to treat adults with previously treated HER2-mutant metastatic NSCLC.

Restrictive Lung Disease

Inhaled Therapy Gets Breakthrough Designation for Non-Cystic Fibrosis Bronchiectasis

Brian Park, PharmD

April 29, 2022

The designation was supported by data from the multicenter, double-blind, placebo-controlled phase 3 PROMIS-I study.

Pneumonia

Pneumococcal 21-Valent Conjugate Vaccine Gets Breakthrough Therapy Status

Brian Park, PharmD

April 21, 2022

The designation was based on data from a phase 1/2 study that evaluated a single intramuscular injection of V116 in pneumococcal-naïve adults.

Critical Care

Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients

Brian Park, PharmD

April 21, 2022

The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.

General Medicine

FDA: Sotrovimab No Longer Authorized to Treat COVID-19 in Any US Region

Brian Park, PharmD

April 19, 2022

As of April 5, 2022, CDC Nowcast data reported that the BA.2 subvariant accounted for more than 50% of cases in all US states and territories.

Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.

Lung Cancer

Trial Evaluating Tiragolumab Combo for Extensive-Stage SCLC Misses Endpoint

Brian Park, PharmD

April 13, 2022

Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and suppresses the immune response to cancer.

Next post in Lung Cancer